IP Library Assignment 066377/0654
Patent Assignment
Reel/Frame 066377/0654

Security Interest

Recorded: 2024-01-29 Pages: 16
Assignors
AKEBIA THERAPEUTICS, INC.
Executed: 2024-01-29
KERYX BIOPHARMACEUTICALS, INC.
Executed: 2024-01-29
Assignee
KREOS CAPITAL VII (UK) LIMITED
12 THROGMORTON AVENUE, C/O BLACKROCK INVESTMENT MANAGEMENT (UK) LIMITED - PRIVATE DEBT-EMEA VENTURE & GROWTH LENDING GROUP, LONDON, EC2N 2DL, UNITED KINGDOM
Covered Properties (57)
Prolyl Hydroxylase Inhibitors and Methods of Use
Application: 17/815,391 →
Publication: US 2023/0201178
Prolyl Hydroxylase Inhibitors and Methods of Use
Application: 18/537,481 →
Publication: US 2024/0358691
Compositions and Methods for Treating Anemia
Application: 18/511,042 →
Publication: US 2024/0335434
Process for Preparing [(3-Hydroxypyridine-2-Carbonyl)Amino]Alkanoic Acids, Esters and Amides
Application: 17/589,118 →
Publication: US 2023/0002323
Solid Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid, Compositions, and Uses Thereof
Application: 18/319,287 →
Publication: US 2024/0122910
Compositions and Methods for Treating Anemia
Application: 18/500,471 →
Publication: US 2024/0325361
Therapeutic Methods Using Vadadustat
Application: 18/259,897 →
Publication: US 2024/0325360
Phd Inhibitor Compounds, Compositions, and Use
Application: 17/906,650 →
Publication: US 2023/0227426
Phd Inhibitor Compounds, Compositions, and Use
Application: 17/906,652 →
Publication: US 2023/0159489
Phd Inhibitor Compounds, Compositions, and Their Use
Application: 17/906,653 →
Publication: US 2023/0212138
Treatment of Viral Infections, of Organ Injury, and of Related Conditions Using a Hif Prolyl Hydroxylase Inhibitor or a Hif-Alpha Stabilizer
Application: 17/996,575 →
Publication: US 2023/0218592
Manufacturing Process for 3,5-Dichloropicolinonitrile for Synthesis of Vadadustat
Application: 18/012,012 →
Publication: US 2023/0286918
Phd Inhibitor Compounds, Compositions, and Methods of Use
Application: 18/041,490 →
Publication: US 2023/0295110
Modulation of Drug-Drug Interactions of Vadadustat
Application: 18/279,680 →
Publication: US 2024/0148707
Methods for Treating Viral Infections, Organ Injury, and Related Conditions
Application: 17/974,000 →
Publication: US 2023/0144457
Method for Producing Nitrogen-Containing Heteroarylcarboxamide Acetic Acid Derivative
Application: 17/783,816 →
Publication: US 2023/0159462
Phd Inhibitor Compounds, Compositions, and Methods of Use
Application: 63/612,140 →
Ferric Citrate Dosage Forms
Application: 18/501,536 →
Use of Ferric Citrate in the Treatment of Chronic Kidney Disease Patients
Application: 18/147,240 →
Publication: US 2024/0041816
Use of Ferric Citrate in the Treatment of and the Reduction of Mortality and Morbidity Related to Adverse Cardiac Events in Chronic Kidney Disease Patients
Application: 18/480,876 →
Use of Ferric Citrate in the Treatment of Iron-Deficiency Anemia
Application: 18/069,555 →
Publication: US 2024/0075006
Pediatric Formulations of Ferric Citrate
Application: 18/517,274 →
Publication: US 2024/0100011
Modulation of Drug-Drug Interactions of Vadadustat
Application: 18/001,917 →
Publication: US 2023/0263786
Therapeutic Methods Using Vadadustat
Application: 17/772,856 →
Publication: US 2023/0285374
Process for Preparing 2-[[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino]Acetic Acid
Application: 18/334,101 →
Publication: US 2024/0158354
Prolyl Hydroxylase Inhibitors and Methods of Use
Patent: 47,437 →
Application: 15/875,495 →
Prolyl Hydroxylase Inhibitors and Methods of Use
Patent: 7,811,595 →
Application: 11/821,936 →
Publication: US 2007/0299086
Prolyl Hydroxylase Inhibitors and Methods of Use
Application: 16/119,146 →
Publication: US 2019/0192494
Prolyl Hydroxylase Inhibitors and Methods of Use
Application: 16/908,092 →
Publication: US 2021/0137901
Prolyl Hydroxylase Inhibitors and Methods of Use
Patent: 8,343,952 →
Application: 12/860,073 →
Publication: US 2010/0331303
Prolyl Hydroxylase Inhibitors and Methods of Use
Patent: 8,323,671 →
Application: 12/860,136 →
Publication: US 2010/0331374
Prolyl Hydroxylase Inhibitors and Methods of Use
Patent: 8,598,210 →
Application: 13/681,876 →
Publication: US 2013/0203816
Prolyl Hydroxylase Inhibitors and Method of Use
Patent: 8,722,895 →
Application: 13/859,574 →
Publication: US 2013/0245076
Prolyl Hydroxylase Inhibitors and Methods of Use
Patent: 8,940,773 →
Application: 14/062,011 →
Publication: US 2014/0045899
Prolyl Hydroxylase Inhibitors and Methods of Use
Patent: 9,598,370 →
Application: 14/854,080 →
Publication: US 2016/0009648
Process for Preparing 2-[[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino]Acetic Acid
Application: 17/053,614 →
Publication: US 2021/0070709
Crystal of Hypoxia Inducible Factor 1 Alpha Prolyl Hydroxylase
Patent: 8,050,873 →
Application: 12/473,536 →
Publication: US 2009/0240475
Crystal of Hypoxia Inducible Factor 1 Alpha Prolyl Hydroxylase
Patent: 8,512,972 →
Application: 13/230,548 →
Publication: US 2012/0282627
Crystal of Hypoxia Inducible Factor 1 Alpha Prolyl Hydroxylase
Patent: 7,588,924 →
Application: 11/713,941 →
Publication: US 2008/0124740
Compositions and Methods for Treating Anemia
Application: 14/897,849 →
Publication: US 2016/0143891
Process for Preparing [(3-Hydroxypyridine-2-Carbonyl)Amino]Alkanoic Acids, Esters and Amides
Patent: 9,145,366 →
Application: 13/488,554 →
Publication: US 2012/0309977
Process for Preparing [(3-Hydroxypyridine-2-Carbonyl)Amino]Alkanoic Acids, Esters and Amides
Patent: 9,776,969 →
Application: 14/833,222 →
Publication: US 2015/0361043
Process for Preparing [(3-Hydroxypyridine-2-Carbonyl)Amino]Alkanoic Acids, Esters and Amides
Application: 15/692,255 →
Publication: US 2017/0362178
Process for Preparing [(3-Hydroxypyridine-2-Carbonyl)Amino]Alkanoic Acids, Esters and Amides
Application: 16/352,705 →
Publication: US 2019/0375713
Process for Preparing [(3-Hydroxypyridine-2-Carbonyl)Amino]Alkanoic Acids, Esters and Amides
Application: 16/921,273 →
Publication: US 2021/0122715
Solid Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid, Compositions, and Uses Thereof
Patent: 9,701,636 →
Application: 14/541,284 →
Publication: US 2015/0141467
Solid Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid, Compositions, and Uses Thereof
Patent: 9,987,262 →
Application: 15/608,186 →
Publication: US 2017/0258773
Solid Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid, Compositions, and Uses Thereof
Application: 15/994,348 →
Publication: US 2018/0280365
Solid Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid, Compositions, and Uses Thereof
Application: 16/178,191 →
Publication: US 2019/0290624
Solid Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid, Compositions, and Uses Thereof
Application: 16/786,187 →
Publication: US 2020/0345711
Solid Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid, Compositions, and Uses Thereof
Application: 17/347,700 →
Publication: US 2022/0040159
Solid Forms of 2-(5-(3-Fluorophenyl)-3-Hydroxypicolinamido)Acetic Acid, Compositions, and Uses Thereof
Application: 15/004,034 →
Publication: US 2016/0214939
Compositions and Methods for Treating Anemia
Application: 15/563,169 →
Publication: US 2018/0092892
Compositions and Methods for Treating Anemia
Application: 17/712,709 →
Publication: US 2023/0071553
Solid Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid
Application: 17/095,998 →
Publication: US 2021/0206721
Ferric Citrate Dosage Forms
Patent: 9,387,191 →
Application: 13/255,326 →
Publication: US 2012/0115945
Ferric Citrate Dosage Forms
Application: 15/159,008 →
Publication: US 2016/0263075
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Feb 2, 2022
From: LANTHIER, CHRISTOPHER M.; GORIN, BORIS; OUDENES, JAN; DIXON, CRAIG EDWARD
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 058868/0265 →
Assignment of Assignor's Interest Jun 13, 2022
From: FUKUHARA, KOHKI; KISHIDA, MUNEKI; MORODA, ATSUSHI; OOTSUKI, KAZUFUMI
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 060182/0597 →
Assignment of Assignor's Interest Jun 14, 2022
From: DEGOMA, EMIL
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 060195/0916 →
Assignment of Assignor's Interest Jun 14, 2022
From: KANEKO, GENKI; MARUYAMA, NOBUKO
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 060196/0114 →
Assignment of Assignor's Interest Jul 28, 2022
From: THE PROCTOR & GAMBLE COMPANY
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 061002/0212 →
Assignment of Assignor's Interest Jul 28, 2022
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 060660/0687 →
Assignment of Assignor's Interest Jul 28, 2022
From: WU, SHENGDE; WARSHAKOON, NAMAL C.; EVDOKIMOV, ARTEM G.; GREIS, KENNETH D.
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 060660/0322 →
Assignment of Assignor's Interest Jul 28, 2022
From: KAWAMOTO, RICHARD MASARU
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 060660/0191 →
Assignment of Assignor's Interest Jul 29, 2022
From: MITSUBISHI TANABE PHARMA CORPORATION
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 060674/0065 →
Assignment of Assignor's Interest Sep 30, 2022
From: FLEMING, PAUL E.; BLAISDELL, THOMAS P.; ALLU, SENKARA RAO
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 061267/0186 →
Assignment of Assignor's Interest Sep 30, 2022
From: FLEMING, PAUL E.; BLAISDELL, THOMAS P.; ALLU, SENKARA RAO
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 061264/0927 →
Assignment of Assignor's Interest Sep 30, 2022
From: FLEMING, PAUL E.; BLAISDELL, THOMAS P.; ALLU, SENKARA RAO
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 061266/0818 →
Assignment of Assignor's Interest Dec 27, 2022
From: BURKE, STEVEN; RABINOWITZ, MICHAEL
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 062212/0302 →
Assignment of Assignor's Interest Jan 26, 2023
From: BURKE, STEVEN; RABINOWITZ, MICHAEL
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 062493/0789 →
Assignment of Assignor's Interest Jan 31, 2023
From: CHAVAN, AJIT; SAWANT, RISHIKESH
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 062543/0466 →
Assignment of Assignor's Interest Jan 31, 2023
From: KOKADO, YOSHIMASA; NANJO, TAKEHIRO; KINOSHITA, SHUJI; KONISHI, NAOMI
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 062543/0448 →
Assignment of Assignor's Interest Feb 13, 2023
From: PORADOSU, ENRIQUE; OLIVIERO, III, JAMES F.; BENTSUR, RON
To: KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 062672/0612 →
Thirteenth Amended and Restated Intellectual Property Security Agreement Mar 29, 2023
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063189/0065 →
Assignment of Assignor's Interest Jun 6, 2023
From: COPP, JAMES DENSMORE; NEWMAN, ANN W.; LUONG, ANNE
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 063861/0223 →
Assignment of Assignor's Interest Jun 9, 2023
From: BLAISDELL, THOMAS P.; ALLU, SENKARA RAO; FLEMING, PAUL E.
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 063912/0548 →
Assignment of Assignor's Interest Jun 30, 2023
From: BURKE, STEVEN; CHAVAN, AJIT; KHAWAJA, ZEESHAN
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 064129/0736 →
Assignment of Assignor's Interest Sep 20, 2023
From: CHAVAN, AJIT; BURKE, STEVEN
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 064967/0244 →
Assignment of Assignor's Interest Sep 20, 2023
From: PORADOSU, ENRIQUE; BENTSUR, RON; SHEMESH, SHAY DAVID
To: KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 064963/0220 →
Assignment of Assignor's Interest Oct 6, 2023
From: PORADOSU, ENRIQUE; OLIVIERO, JAMES F., III; BENTSUR, RON
To: KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 065147/0549 →
Assignment of Assignor's Interest Nov 6, 2023
From: CHANDORKAR, GURUDATT AJAY
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 065469/0854 →